MX384070B - Proteínas de fusión de inhibidor de tripsina urinaria (uti). - Google Patents
Proteínas de fusión de inhibidor de tripsina urinaria (uti).Info
- Publication number
- MX384070B MX384070B MX2020000537A MX2020000537A MX384070B MX 384070 B MX384070 B MX 384070B MX 2020000537 A MX2020000537 A MX 2020000537A MX 2020000537 A MX2020000537 A MX 2020000537A MX 384070 B MX384070 B MX 384070B
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- uti
- trypsin inhibitor
- urinary trypsin
- urinary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943617P | 2014-02-24 | 2014-02-24 | |
| PCT/US2015/017152 WO2015127391A1 (en) | 2014-02-24 | 2015-02-23 | Uti fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX384070B true MX384070B (es) | 2025-03-14 |
Family
ID=52629709
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000537A MX384070B (es) | 2014-02-24 | 2015-02-23 | Proteínas de fusión de inhibidor de tripsina urinaria (uti). |
| MX2016010950A MX2016010950A (es) | 2014-02-24 | 2015-02-23 | Proteinas de fusion de inhibidor de tripsina urinaria (uti). |
| MX2019013124A MX2019013124A (es) | 2014-02-24 | 2016-08-23 | Proteinas de fusion de inhibidor de tripsina urinaria (uti). |
| MX2024000004A MX2024000004A (es) | 2014-02-24 | 2016-08-23 | Proteinas de fusion de inhibidor de tripsina urinaria (uti). |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010950A MX2016010950A (es) | 2014-02-24 | 2015-02-23 | Proteinas de fusion de inhibidor de tripsina urinaria (uti). |
| MX2019013124A MX2019013124A (es) | 2014-02-24 | 2016-08-23 | Proteinas de fusion de inhibidor de tripsina urinaria (uti). |
| MX2024000004A MX2024000004A (es) | 2014-02-24 | 2016-08-23 | Proteinas de fusion de inhibidor de tripsina urinaria (uti). |
Country Status (38)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3110434T3 (pl) * | 2014-02-24 | 2019-01-31 | Takeda Gmbh | Białka fuzyjne uti |
| WO2018226887A1 (en) | 2017-06-07 | 2018-12-13 | Spark Therapeutics, Inc. | ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION |
| WO2020106881A1 (en) * | 2018-11-20 | 2020-05-28 | Diamedica Inc. | Modified ulinastatin polypeptides |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| US11725043B2 (en) | 2020-03-05 | 2023-08-15 | DiaMedica USA Inc. | Ulinastatin polypeptides |
| WO2022165031A1 (en) * | 2021-01-29 | 2022-08-04 | DiaMedica USA Inc. | Ulinastatin polypeptides for treating diseases |
| CN116903721A (zh) * | 2023-06-16 | 2023-10-20 | 成都佩德生物医药有限公司 | 多肽pdbpe-001、其药物组合物和用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| DK0401508T3 (da) * | 1989-05-13 | 1995-05-15 | Bayer Ag | Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf |
| CA2055425A1 (en) | 1990-11-13 | 1992-05-14 | Hideaki Morishita | Polypeptide, dna fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same |
| JP2769083B2 (ja) | 1993-02-22 | 1998-06-25 | 日清食品株式会社 | エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法 |
| JP3469584B2 (ja) | 1996-03-11 | 2003-11-25 | バイエル コーポレイション | ヒト ビクニン |
| DE19725014A1 (de) | 1997-06-13 | 1998-12-17 | Bayer Ag | Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten |
| PT1730191E (pt) * | 2004-03-30 | 2011-10-04 | Glaxo Group Ltd | Imunoglobulina que se liga a hosm |
| AU2005334481A1 (en) | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| CA2609262A1 (en) * | 2005-06-03 | 2006-12-07 | Mochida Pharmaceutical Co., Ltd. | Anti-cd14 antibody fusion protein |
| PL1981519T3 (pl) | 2005-12-29 | 2018-07-31 | Dyax Corp. | Hamowanie proteaz |
| CA2737241C (en) * | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| CN101721699B (zh) * | 2008-10-13 | 2012-11-07 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用 |
| CN102580085B (zh) * | 2008-10-13 | 2013-09-18 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗脓毒症药物中的应用 |
| WO2010129600A2 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| HUE030100T2 (en) * | 2010-02-19 | 2017-04-28 | Xencor Inc | New CTLA4-IG immunoadhesins |
| ES2666303T3 (es) * | 2011-04-29 | 2018-05-03 | University Of Washington | Composiciones terapéuticas de nucleasa y métodos |
| US8619331B2 (en) | 2011-07-19 | 2013-12-31 | Xerox Corporation | Simulated paper texture using clear toner and glossmark on texture-less stock |
| ES2651521T3 (es) * | 2011-12-01 | 2018-01-26 | Innovent Biologics, Inc. | Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos |
| CA2871468C (en) * | 2012-04-23 | 2021-09-21 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
| JP2013253079A (ja) * | 2012-05-14 | 2013-12-19 | Xuhua (Shanghai) Biological Research & Development Center Co Ltd | 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用 |
| CN103044554B (zh) * | 2012-05-14 | 2014-08-27 | 旭华（上海）生物研发中心有限公司 | 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用 |
| PL3110434T3 (pl) * | 2014-02-24 | 2019-01-31 | Takeda Gmbh | Białka fuzyjne uti |
-
2015
- 2015-02-23 PL PL15708411T patent/PL3110434T3/pl unknown
- 2015-02-23 MY MYPI2016703046A patent/MY178774A/en unknown
- 2015-02-23 HR HRP20182029TT patent/HRP20182029T1/hr unknown
- 2015-02-23 KR KR1020247035230A patent/KR20240155987A/ko active Pending
- 2015-02-23 US US15/120,956 patent/US9856310B2/en active Active
- 2015-02-23 NZ NZ760789A patent/NZ760789A/en unknown
- 2015-02-23 NZ NZ724196A patent/NZ724196A/en unknown
- 2015-02-23 NZ NZ760008A patent/NZ760008A/en unknown
- 2015-02-23 GE GEAP201814277A patent/GEAP201814277A/en unknown
- 2015-02-23 EP EP18192690.8A patent/EP3443978A1/en not_active Withdrawn
- 2015-02-23 SM SM20180674T patent/SMT201800674T1/it unknown
- 2015-02-23 CA CA2939639A patent/CA2939639C/en active Active
- 2015-02-23 EA EA201691702A patent/EA037256B1/ru unknown
- 2015-02-23 MX MX2020000537A patent/MX384070B/es unknown
- 2015-02-23 BR BR112016019390-3A patent/BR112016019390B1/pt active IP Right Grant
- 2015-02-23 SG SG11201606691QA patent/SG11201606691QA/en unknown
- 2015-02-23 PE PE2016001522A patent/PE20170257A1/es unknown
- 2015-02-23 MX MX2016010950A patent/MX2016010950A/es active IP Right Grant
- 2015-02-23 UA UAA201609101A patent/UA118866C2/uk unknown
- 2015-02-23 EA EA202091567A patent/EA202091567A1/ru unknown
- 2015-02-23 CR CR20160444A patent/CR20160444A/es unknown
- 2015-02-23 SG SG10201708400QA patent/SG10201708400QA/en unknown
- 2015-02-23 KR KR1020227037377A patent/KR102722304B1/ko active Active
- 2015-02-23 RS RS20181514A patent/RS58285B1/sr unknown
- 2015-02-23 GE GEAP201514277A patent/GEP20196970B/en unknown
- 2015-02-23 SI SI201530516T patent/SI3110434T1/sl unknown
- 2015-02-23 CN CN201580014645.3A patent/CN106232135B/zh active Active
- 2015-02-23 EP EP15708411.2A patent/EP3110434B1/en active Active
- 2015-02-23 PT PT15708411T patent/PT3110434T/pt unknown
- 2015-02-23 CA CA3178241A patent/CA3178241A1/en active Pending
- 2015-02-23 ES ES15708411T patent/ES2700149T3/es active Active
- 2015-02-23 WO PCT/US2015/017152 patent/WO2015127391A1/en not_active Ceased
- 2015-02-23 KR KR1020167026429A patent/KR102461210B1/ko active Active
- 2015-02-23 PH PH1/2016/501629A patent/PH12016501629B1/en unknown
- 2015-02-23 DK DK15708411.2T patent/DK3110434T3/en active
- 2015-02-23 MA MA39347A patent/MA39347B2/fr unknown
- 2015-02-23 JP JP2016553562A patent/JP6574431B2/ja active Active
- 2015-02-23 CN CN201910282497.3A patent/CN110092837B/zh active Active
- 2015-02-23 LT LTEP15708411.2T patent/LT3110434T/lt unknown
- 2015-02-23 AU AU2015218704A patent/AU2015218704B2/en active Active
- 2015-08-20 JO JOP/2015/0200A patent/JO3729B1/ar active
- 2015-08-20 AR ARP150102677A patent/AR101597A1/es unknown
- 2015-08-21 TW TW104127393A patent/TWI694084B/zh active
-
2016
- 2016-08-10 DO DO2016000202A patent/DOP2016000202A/es unknown
- 2016-08-17 IL IL247321A patent/IL247321B/en active IP Right Grant
- 2016-08-23 MX MX2019013124A patent/MX2019013124A/es unknown
- 2016-08-23 MX MX2024000004A patent/MX2024000004A/es unknown
- 2016-08-24 CL CL2016002136A patent/CL2016002136A1/es unknown
- 2016-09-13 ZA ZA2016/06327A patent/ZA201606327B/en unknown
- 2016-09-23 EC ECIEPI201676535A patent/ECSP16076535A/es unknown
-
2017
- 2017-11-27 US US15/823,398 patent/US10351618B2/en active Active
-
2018
- 2018-12-18 CY CY181101355T patent/CY1120997T1/el unknown
-
2019
- 2019-02-15 US US16/277,606 patent/US20200040062A1/en not_active Abandoned
- 2019-06-11 JP JP2019109054A patent/JP6938565B2/ja active Active
- 2019-06-25 AU AU2019204448A patent/AU2019204448B2/en active Active
-
2021
- 2021-06-03 US US17/337,922 patent/US20220127334A1/en not_active Abandoned
- 2021-08-31 AU AU2021225156A patent/AU2021225156B2/en active Active
- 2021-09-01 JP JP2021142544A patent/JP2022002513A/ja active Pending
-
2023
- 2023-02-16 AU AU2023200875A patent/AU2023200875A1/en not_active Abandoned
- 2023-06-30 JP JP2023108024A patent/JP2023123763A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202107931B (en) | Anti-tau antibodies and methods of use | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| MX2024000300A (es) | Anticuerpos antitau y metodos de uso. | |
| MX384070B (es) | Proteínas de fusión de inhibidor de tripsina urinaria (uti). | |
| MY198059A (en) | Anti-ox40 antibodies and their uses | |
| BR112019012343A2 (pt) | anticorpos il-11ra | |
| MY193661A (en) | Anti-tim3 antibodies and methods of use | |
| MX2019006330A (es) | Anticuerpos anti-tau y metodos de uso. | |
| MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
| BR112017013568A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
| PH12017501815B1 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. | |
| EP4467565A3 (en) | Anti-tnf alpha antibody formulations | |
| UY36277A (es) | Proteínas de fusión uti | |
| BR112017010627A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
| UA97936U (uk) | Спосіб реконструктивного етапу панкреатодуоденальної резекції |